Back to results
US 2013/0096173 A1Published application
Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
OwnerBankole A. Johnsoninventor
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods useful for diagnosing, treating, and monitoring alcohol dependence and disorders and susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders.
Claims28
A method of treating an addictive disease or disorder, comprising:
- administering to a patient in need thereof a therapeutically effective amount of an antagonist of the serotonin receptor 5-HT3, wherein the patient's serotonin transporter gene SLC6A4 is known to have a genotype selected from sets (a)-(q):
- (a.) the AA genotype of rs1176719 and the AG genotype of rs1150226;
- (b.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the AC genotype of rs17614942;
- (c.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;
- (d.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the AC genotype of rs17614942 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;
- (e.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the GG genotype of rs1176713 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;
- (f.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the AC genotype of rs17614942 and the GG genotype of rs1176713 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;
- (g.) the AA genotype of rs1176719 and the GG genotype of rs1176713;
- (h.) the AA genotype of rs1176719 and the GG genotype of rs1176713 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;
- (i.) the AA genotype of rs1176719 and the GG genotype of rs1176713 and the AC genotype of rs17614942 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;
- (j.) the GG genotype of rs1176713 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;
- (k.) the GG genotype of rs1176713 and the AG genotype of rs1150226 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;
- (l.) the GG genotype of rs1176713 and the AC genotype of rs17614942 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;
- (m.) the GG genotype of rs1176713 and the AG genotype of rs1150226 and the AC genotype of rs17614942 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;
- (n.) the AG genotype of rs1150226 and the AA genotype of rs1176719 and the AC genotype of rs17614942 and the GG genotype of rs1176713;
- (o.) the AG genotype of rs1150226 and the AA genotype of rs1176719 and the GG genotype of rs1176713;
- (p.) the AG genotype of rs1150226 and the AC genotype of rs17614942 and the GG genotype of rs1176713;
- and,
- (q.) the AA genotype of rs1176719 and the AC genotype of rs17614942 and the GG genotype of rs1176713.
16 more elements
A method of selecting patients with an addictive disease or disorder who will be responsive to treatment with an antagonist of the serotonin receptor 5-HT3, comprising:
- determining whether the patient's serotonin transporter gene SLC6A4 has a genotype set selected from sets (a)-(q):
- (a.) the AA genotype of rs1176719 and the AG genotype of rs1150226;
- (b.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the AC genotype of rs17614942;
- (c.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;
- (d.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the AC genotype of rs17614942 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;
- (e.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the GG genotype of rs1176713 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;
- (f.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the AC genotype of rs17614942 and the GG genotype of rs1176713 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;
- (g.) the AA genotype of rs1176719 and the GG genotype of rs1176713;
- (h.) the AA genotype of rs1176719 and the GG genotype of rs1176713 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;
- (i.) the AA genotype of rs1176719 and the GG genotype of rs1176713 and the AC genotype of rs17614942 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;
- (j.) the GG genotype of rs1176713 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;
- (k.) the GG genotype of rs1176713 and the AG genotype of rs1150226 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;
- (l.) the GG genotype of rs1176713 and the AC genotype of rs17614942 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;
- (m.) the GG genotype of rs1176713 and the AG genotype of rs1150226 and the AC genotype of rs17614942 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173;
- (n.) the AG genotype of rs1150226 and the AA genotype of rs1176719 and the AC genotype of rs17614942 and the GG genotype of rs1176713;
- (o.) the AG genotype of rs1150226 and the AA genotype of rs1176719 and the GG genotype of rs1176713;
- (p.) the AG genotype of rs1150226 and the AC genotype of rs17614942 and the GG genotype of rs1176713;
- and,
- (q.) the AA genotype of rs1176719 and the AC genotype of rs17614942 and the GG genotype of rs1176713.
16 more elements
Dependencies are inferred from the claim text.